Data gathered: December 26
AI Stock Analysis - Incyte (INCY)
Analysis generated June 17, 2024. Powered by Chat GPT.
Incyte Corporation (INCY) is a well-established biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The firm's portfolio includes products aimed at treating various cancer types, inflammatory diseases, and more. Incyte leverages its strong research and development capabilities to maintain a competitive edge in an evolving market.
Stock Alerts - Incyte (INCY)
 |
Incyte | December 18 Insider Alert: Tray Thomas is selling shares |
|
Incyte | December 9 Price is down by -5% in the last 24h. |
|
Incyte | December 4 Insider Alert: Iyengar Vijay K is selling shares |
|
Incyte | December 4 Employee Rating is up by 2.6% over the last month. |
Alternative Data for Incyte
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 70 | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 48,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 26 | Sign up | Sign up | Sign up |
| Patents | 516 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 143 | Sign up | Sign up | Sign up |
| Facebook Followers | 4,739 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,327 | Sign up | Sign up | Sign up |
| Twitter Followers | 6,501 | Sign up | Sign up | Sign up |
| Twitter Mentions | 27 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 239 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 56 | Sign up | Sign up | Sign up |
| Linkedin Employees | 2,942 | Sign up | Sign up | Sign up |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally.
| Price | $69.74 |
| Target Price | Sign up |
| Volume | 34,950 |
| Market Cap | $13.5B |
| Year Range | $51.18 - $83.38 |
| Dividend Yield | 0% |
| PE Ratio | 776.78 |
| Analyst Rating | 37% buy |
| Industry | Biotechnology |
In the news
 |
Incyte (NASDAQ:INCY) Given New $70.00 Price Target at Wells Fargo & CompanyDecember 20 - ETF Daily News |
Incyte price target raised to $70 from $68 at Wells FargoDecember 19 - Yahoo |
|
|
Incyte Co. (NASDAQ:INCY) Given Average Recommendation of “Hold” by BrokeragesDecember 18 - ETF Daily News |
 |
Incyte initiated with neutral view at UBS, here's whyDecember 17 - Thefly.com |
 |
Incyte to Present at Upcoming Investor ConferenceDecember 16 - Yahoo |
 |
Incyte (NASDAQ:INCY) Receives Outperform Rating from William BlairDecember 15 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 1.14B | 86M | 1.05B | 106M | 180M | 1.070 |
| Q2 '24 | 1.04B | 93M | 951M | -445M | -367M | -1.820 |
| Q1 '24 | 880M | 61M | 820M | 170M | 114M | 0.640 |
| Q4 '23 | 1.01B | 70M | 943M | 201M | 294M | 1.060 |
| Q3 '23 | 918M | 60M | 858M | 171M | 261M | 1.100 |
Insider Transactions View All
| Tray Thomas filed to sell 23,312 shares at $69.3. December 17 '24 |
| Iyengar Vijay K filed to sell 36,341 shares at $75.6. December 3 '24 |
| Iyengar Vijay K filed to sell 30,658 shares at $75.4. December 3 '24 |
| Flannelly Barry P filed to sell 60,298 shares at $82. November 8 '24 |
| Flannelly Barry P filed to sell 58,042 shares at $78.2. November 8 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Ro Khanna |
Oct 8, 24 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Sell | $1K - $15K |
Read more about Incyte (INCY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Incyte?
The Market Cap of Incyte is $13.5B.
What is Incyte's PE Ratio?
As of today, Incyte's PE (Price to Earnings) ratio is 776.78.
What is the current stock price of Incyte?
Currently, the price of one share of Incyte stock is $69.74.
How can I analyze the INCY stock price chart for investment decisions?
The INCY stock price chart above provides a comprehensive visual representation of Incyte's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Incyte shares. Our platform offers an up-to-date INCY stock price chart, along with technical data analysis and alternative data insights.
Does INCY offer dividends to its shareholders?
As of our latest update, Incyte (INCY) does not offer dividends to its shareholders. Investors interested in Incyte should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Incyte?
Some of the similar stocks of Incyte are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.